Magnetic Resonance Imaging for Breast Lumpectomy Cavity Delineation: Computed Tomography Comparison and Sequence Variation

Abstract

deterioration, and 16 (16%) stability in EF values compared to the baseline. Age (50 vs >50), menopausal status, tobacco use, history of DM and HT, multiple medication use, tumor location, stage, HRT use, presence of axilla and MI in the RT field, RT technique, median heart dose (5 Gy vs >5 Gy), V10 (10% vs >10%), V20 (3% vs >3%) and V30 (1% vs >1%) were not effective on the variation in EF in both the first and last controls. When the patients with right-and left-sided tumors were compared; although the median heart dose and the number of patients receiving RT to the MI region were higher in patients with leftsided tumors, EF values in the first and last controls were similar to the patients with right-sided tumors. Conclusion: We observed that concurrent use of trastuzumab with RT did not increase the risk of cardiac toxicity. Therefore, trastuzumab can be used safely in patients with breast cancer who will undergo adjuvant RT.